On August 24, AKESO rose 3.49% in regular trading, trading at HK$92.55/share, with turnover of HK$88.28 million. The rebound follows a nearly 4% decline in the prior session.

On the news front, the company is scheduled to release its interim results on August 27, with market focus on the commercialization pace of ivonescimab following its third indication approval for first-line squamous NSCLC on August 12. Additionally, the company's self-developed AK157d1 (B7-H3 ADC) recently received approval to initiate a Phase I clinical trial in solid tumors, expanding its differentiated ADC pipeline to three candidates and reinforcing pipeline depth.

Institutional coverage remains broadly positive, with analysts maintaining buy ratings and an average target price of HK$170.79, implying significant upside from current levels. The stock had previously pulled back over 10% from highs following profit-taking after the third indication approval, creating technical oversold conditions that, combined with the earnings catalyst and pipeline developments, appear to have prompted capital re-entry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)